Filter
1376
Text search:
drug
regimens
Featured
154
354
Language
Document type
914
192
161
39
24
21
12
7
3
2
1
Countries / Regions
77
42
38
34
33
31
26
25
25
23
22
19
18
18
17
15
14
14
13
13
12
12
12
12
11
10
10
9
9
8
7
6
5
5
5
5
5
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
448
226
58
53
29
13
5
Toolboxes
296
290
52
49
41
30
23
22
18
17
11
11
7
7
6
4
3
3
2
2
2
1
This study consists of a descriptive analysis of M. tuberculosis isolates from Beira Central Hospital, Mozambique, during 2014–2015, being the first report of a genotypic testing used to provide information about second line drug resistance in Moz
...
12-13 December 2016
Global Action Plan on HIV Drug Resistance - Webinars 12-13 December 2016
This e-course will guide you through the essentials of latest existing WHO guidelines and policy recommendations on drug-resistant TB. You will also learn more about the rationale behind the WHO recommendations for the management of DR-TB, implement
...
PLOS ONE | DOI:10.1371/journal.pone.0144057 December 14, 2015
The guidelines are aimed at clinical professionals directly involved with and responsible for the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA
...
These guidelines group all recommendations on TB care and support in one document and are complemented by an operational handbook. The guidelines are to be used primarily by national TB programmes, or their equivalents in Ministries of Health, stakeholders and technical organizations working on
...
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of
...
Technical information note. Ensuring an uninterrupted supply of quality-assured, affordable anti-TB
drugs and diagnostics to the world
Preventing tuberculosis infection from progressing to tuberculosis disease is a crucial component of the goal to eliminate tuberculosis. When deciding on the use of tuberculosis preventive therapy among household contacts, policy makers regularly ask questions, such as whether tuberculosis preventiv
...
The new, all oral, 20-month MDR-TB regimens range from US $1,600* (using bedaquiline and linezolid for 6 months and levofloxacin as the fluoroquinolone) to US $2,100* (using linezolid for 12 months and moxifloxacin as the fluoroquinolone.
Cardiovascular disease (CVD) is the leading cause of global deaths, with the majority occurring in low- and middle-income countries (LMIC). The primary and secondary prevention of CVD is suboptimal throughout the world, but the evidence-practice gaps are much more pronounced in LMIC. Barriers at the
...
Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis (LF). This communi
...
